ITM Isotope Technologies Engages with Investors
ITM Isotope Technologies Munich SE (ITM), a trailblazer in the field of radiopharmaceuticals, has announced its forthcoming participation in noteworthy industry investor conferences. As a leading biotech entity, ITM focuses on delivering cutting-edge radiomolecular precision therapeutics, which play a crucial role in battling hard-to-treat tumors.
Details of the Conferences
ITM's Chief Executive Officer, Dr. Andrew Cavey, and Chief Financial Officer, Dr. Klaus Maleck, are set to represent the company at these events. Their attendance is a vital part of ITM's strategy to communicate its advancements and to engage with investors directly.
William Blair Investor Conference (Virtual)
Taking place on November 13, 2024, at 9:00 AM ET, Dr. Cavey will be participating in a virtual fireside chat. This session will provide insights into ITM's innovative approaches within the radiopharmaceutical space. Additionally, Dr. Cavey and Dr. Maleck will be hosting one-on-one meetings with conference attendees, allowing for deeper discussions regarding ITM's future and projects.
Jefferies London Healthcare Conference 2024
From November 19 to 21, 2024, ITM executives will also be present at the Jefferies London Healthcare Conference. This gathering will further facilitate direct interactions, enabling potential investors to gain comprehensive insights into ITM's ongoing initiatives, particularly around their research and development pipeline.
About ITM Isotope Technologies Munich SE
ITM prides itself on niche expertise in the development and supply of precision radiotherapies. The company is dedicated to meeting the needs of patients and healthcare providers by engaging in relentless innovation aimed at improving treatment outcomes and quality of life for cancer patients. ITM's precision oncology pipeline is robust, featuring several phase III studies that integrate high-quality radioisotopes with various targeting molecules, reflective of ITM's commitment to enhancing therapeutic effectiveness.
Contact Information
If you are looking for more information or have inquiries regarding ITM's participation in these conferences, please reach out to:
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com
Media Contact
Corporate Communications
Kathleen Noonan/Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com
Frequently Asked Questions
What is ITM’s focus in the biotech industry?
ITM focuses on developing radiopharmaceuticals that offer targeted treatments for challenging tumors.
When are the upcoming conferences?
The William Blair Investor Conference is on November 13, 2024, and the Jefferies London Healthcare Conference is from November 19 to 21, 2024.
Who are the key speakers representing ITM?
Dr. Andrew Cavey (CEO) and Dr. Klaus Maleck (CFO) will represent ITM at both conferences.
How does ITM contribute to cancer treatment?
ITM develops precision therapeutics and diagnostics aimed at improving patient outcomes in oncology.
What can investors expect from these conferences?
Investors can expect insightful presentations and opportunities for direct engagement with ITM’s leadership regarding the company's future direction.
